Project Grant R01CA292523
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$442K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to evaluate the effectiveness of a precision prevention intervention to improve skin cancer prevention activities in diverse patients at Federally Qualified Health Centers in Tampa, Florida. The $706,771 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a hybrid effectiveness-implementation study over 5 years,...
This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a clinical decision support tool to understand the survival benefit of kidney transplantation in candidates with a history of cancer. The $348,657 award to the Hennepin Healthcare Research Institute (HHRI) in Minneapolis, MN, with a sub-award to the University of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $958,434 to The Leland Stanford Junior University to conduct research aimed at understanding the molecular mechanisms of receptor tyrosine kinase RET regulation in human epidermis and defining RET-regulated impacts on the tumor immune microenvironment. The overarching objective is to develop therapeutic strategies, such as RET inhibition, for effective secondary prevention of...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), aims to develop enhanced cancer risk prediction models for underrepresented populations, particularly Black and Hispanic individuals. The $432,304 grant, awarded on January 3, 2025, will fund the development of novel data integration and machine learning methods to effectively leverage multi-source electronic health record (EHR) and biobank data. The...
This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $602,315.00 to validate a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test new lung cancer prevention agents. The key objectives are to: 1) Define the human relevance of the in vivo NTCU/smoke mouse model of lung SCC premalignancy, 2) Validate an ex vivo precision-cut lung slice approach to screen new prevention agents using...
The federal Project Grant award R01CA283469, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to study the relationship between human leukocyte antigen (HLA) diversity and cancer risk. The $1,964,029 award, which spans from June 1, 2024 to May 31, 2029, will investigate how HLA diversity impacts the efficiency of tumor immune surveillance and its effect on the risk of lung cancer and melanoma. The research...
This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program, supports research to develop new cell culture models for studying Kaposi's sarcoma, a cancer caused by the Kaposi's sarcoma-associated herpesvirus (KSHV). The $411,400 award to Northwestern University will be used to identify KSHV-induced human genes that promote the loss of contact inhibition of proliferation in KSHV-infected lymphatic endothelial cells (KLECs), a...
This Project Grant award of $661,302 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of a comprehensive prognostic model for predicting cervical cancer treatment response and outcomes. The key products and services to be delivered include: Identifying unimodal biomarkers from radiologic/histologic imaging and RNA analyses to predict cervical cancer treatment response and outcomes. Developing an advanced prognostic...
This $2,282,687 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to understand how various forms of integration (structural, functional, normative, interpersonal, and process) in oncology care delivery are associated with quality and outcomes. The research will examine integration across different healthcare settings, including health systems, independent oncology practices, post-acute/hospice care, and specialty pharmacies....
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...